Dr Natansh Modi

Lecturer, Pharmacy

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.


Dr Natansh Deepak Modi is a Lecturer in Pharmacy at the Adelaide University, where he teaches and coordinates Health Professional Essentials and Pharmacology C.
His research focuses on transparency and accessibility in clinical trials, with a particular emphasis on oncology. He asks fundamental questions about who benefits from healthcare systems and how data sharing can lead to more equitable outcomes for patients. As a registered pharmacist, Dr Modi brings clinical experience into his teaching. He emphasises the importance of communication, patient-centred care and the ethical dimensions of pharmaceutical practice. His work also examines how patient-reported outcomes can inform treatment decisions and how shared trial data can enhance care for populations that are often underrepresented in research.
Dr Modi is Executive Director of the Clinical Oncology Society of Australia's Epidemiology Committee and serves as a reviewer for major medical journals. His experiences have shaped his belief that healthcare systems should function better for everyone, especially those lacking privilege or resources.

Year Citation
2025 Menz, B. D., Modi, N. D., Abuhelwa, A. Y., Kuderer, N. M., Lyman, G. H., Swain, S. M., . . . Hopkins, A. M. (2025). Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials. International Journal of Cancer, 157(10), 2135-2145.
DOI Scopus1 Europe PMC2
2025 Modi, N. D., Li, L. X., Logan, J. M., Wiese, M. D., Abuhelwa, A. Y., McKinnon, R. A., . . . Hopkins, A. M. (2025). The state of individual participant data sharing for the highest-revenue medicines. Clinical Trials, 22(2), 170-177.
DOI
2025 Menz, B. D., Modi, N. D., Abuhelwa, A. Y., Ruanglertboon, W., Vitry, A., Gao, Y., . . . Hopkins, A. M. (2025). Generative AI Chatbots for Reliable Cancer Information: Evaluating web-search, multilingual, and reference capabilities of emerging large language models. European Journal of Cancer, 218, 115274-1-115274-6.
DOI Scopus11 WoS11 Europe PMC6
2025 Chu, B., Modi, N. D., Menz, B. D., Bacchi, S., Kichenadasse, G., Paterson, C., . . . Hopkins, A. M. (2025). Generative AI’s healthcare professional role creep: a cross-sectional evaluation of publicly accessible, customised health-related GPTs. Frontiers in Public Health, 13, 1584348-1-1584348-8.
DOI Scopus2 WoS1
2025 Modi, N. D., Menz, B. D., Awaty, A. A., Alex, C. A., Logan, J. M., McKinnon, R. A., . . . Hopkins, A. M. (2025). Assessing the system-instruction vulnerabilities of large language models to malicious conversion into health disinformation chatbots. Annals of Internal Medicine, 178(8), 1172-1180.
DOI Scopus4 Europe PMC3
2025 Modi, N. D., Abuhelwa, A. Y., Kuderer, N. M., Li, L. X., Lyman, G. H., Koczwara, B., . . . Hopkins, A. M. (2025). Associations of commonly used concomitant medications with survival and adverse event outcomes in breast cancer. Cancer Medicine, 14(21, article no. e71320), 1-10.
DOI Europe PMC1
2025 Modi, N. D. (2025). Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. American College of Cardiology. Journal, online(22), 1-77.
DOI Scopus33 Europe PMC8
2024 Menz, B. D., Kuderer, N. M., Bacchi, S., Modi, N. D., Chin-Yee, B., Hu, T., . . . Hopkins, A. M. (2024). Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysis. BMJ, 384(e078538), e078538-1-e078538-10.
DOI Scopus64 WoS56 Europe PMC43
2024 Modi, N. D., Swain, S. M., Buyse, M., Kuderer, N. M., Rowland, A., Rockhold, F. W., . . . Hopkins, A. M. (2024). Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability. Journal of Clinical Oncology, 42(32), 3773-3777.
DOI Scopus6 Europe PMC7
2024 Hopkins, A. M., Modi, N. D., Rockhold, F. W., Hoffmann, T., Menz, B. D., Veroniki, A. A., . . . Sorich, M. J. (2024). Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation. Journal Of Clinical Epidemiology, 167(111263), 1-9.
DOI Scopus5 Europe PMC3
2024 Menz, B. D., Modi, N. D., Sorich, M. J., & Hopkins, A. M. (2024). Health disinformation use case highlighting the urgent need for artificial intelligence vigilance: weapons of mass disinformation. JAMA Internal Medicine, 184(1), 92-96.
DOI Scopus63 Europe PMC41
2024 Almansour, S. A., Alqudah, M. A. Y., Abuhelwa, Z., Al Shamsi, H. O., Alhuraiji, A., Semreen, M. H., . . . Abuhelwa, A. Y. (2024). Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Therapeutic Advances in Medical Oncology, 16, 1-14.
DOI Scopus1
2023 Modi, N. D., Kichenadasse, G., Hoffmann, T. C., Haseloff, M., Logan, J. M., Veroniki, A. A., . . . Hopkins, A. M. (2023). A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies. BMC Medicine, 21(1), 400.
DOI Scopus17 Europe PMC12
2023 Hopkins, A. M., Modi, N. D., Abuhelwa, A. Y., Kichenadasse, G., Kuderer, N. M., Lyman, G. H., . . . Sorich, M. J. (2023). Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncology, 9(12), 1621-1626.
DOI Scopus14 Europe PMC12
2023 Modi, N., Abuhelwa, A. Y., Rowland, A., Menz, B. D., McKinnon, R. A., Sorich, M. J., & Hopkins, A. M. (2023). Association between patient-reported outcomes and therapeutic outcomes in patients with breast cancer: A pooled individual-participant data analysis.. Journal of Clinical Oncology, 41(16_suppl), 530.
DOI
2022 Modi, N. D., Abuhelwa, A. Y., Mckinnon, R. A., Boddy, A. V., Haseloff, M., Wiese, M. D., . . . Hopkins, A. M. (2022). Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration. JAMA Oncology, 8(9), 1310-1316.
DOI Scopus17 Europe PMC17
2022 Tan, E., Abuhelwa, A. Y., Badaoui, S., Modi, N. D., Wiese, M. D., Mckinnon, R. A., . . . Hopkins, A. M. (2022). Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. Bladder Cancer, 8(1), 81-88.
DOI Scopus7 Europe PMC7
2022 Modi, N. D., Danell, N. O., Perry, R. N. A., Abuhelwa, A. Y., Rathod, A., Badaoui, S., . . . Hopkins, A. M. (2022). Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer. ESMO Open, 7(3, article no. 100475), 1-8.
DOI Scopus14 Europe PMC12
2021 Modi, N. D., Tan, J. Q. E., Rowland, A., Koczwara, B., Abuhelwa, A. Y., Kichenadasse, G., . . . Hopkins, A. M. (2021). The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. Npj Breast Cancer, 7(1), 30.
DOI Scopus41 Europe PMC33
2021 Modi, N. D., Abuhelwa, A. Y., Menz, B. D., McKinnon, R. A., Sorich, M. J., & Hopkins, A. M. (2021). Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, 732622.
DOI Scopus1 Europe PMC1
2021 Modi, N. D., Abuhelwa, A. Y., Badaoui, S., Shaw, E., Shankaran, K., McKinnon, R. A., . . . Hopkins, A. M. (2021). Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. The Breast, 58, 57-62.
DOI Scopus14 Europe PMC10
2020 Ang, F. L. I., Rowland, A., Modi, N. D., McKinnon, R. A., Sorich, M. J., & Hopkins, A. M. (2020). Early adverse events predict survival outcomes in HER2-positive advanced breast cancer patients treated with Lapatinib plus Capecitabine. Journal of Cancer, 11(11), 3327-3333.
DOI Scopus5 WoS5 Europe PMC5
2020 Hopkins, A. M., Wagner, J., Kichenadasse, G., Modi, N., Rowland, A., & Sorich, M. J. (2020). Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy. International Journal of Cancer, 147(11), 3085-3089.
DOI Scopus34 Europe PMC27
2020 Modi, N. D., Sorich, M. J., Rowland, A., McKinnon, R. A., Koczwara, B., Wiese, M. D., & Hopkins, A. M. (2020). Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. Clinical Breast Cancer, 20(2), e220-e228.
DOI Scopus15 Europe PMC13
2020 Modi, N. D., Sorich, M. J., Rowland, A., Logan, J. M., McKinnon, R. A., Kichenadasse, G., . . . Hopkins, A. M. (2020). A literature review of treatment-specific clinical prediction models in patients with breast cancer. Critical Reviews in Oncology Hematology, 148(102908), 8 pages.
DOI Scopus15 WoS12 Europe PMC11
2020 Modi, N. D., Tan, J. Q. E., Rowland, A., Koczwara, B., Kichenadasse, G., McKinnon, R. A., . . . Hopkins, A. M. (2020). The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. Frontiers in Oncology, 10(1130), 1130.
DOI Scopus13 Europe PMC11
2019 Jin, C., Alenazy, R., Wang, Y., Mowla, R., Qin, Y., Tan, J. Q. E., . . . Ma, S. (2019). Design, synthesis and evaluation of a series of 5-methoxy-2,3-naphthalimide derivatives as AcrB inhibitors for the reversal of bacterial resistance. Bioorganic and Medicinal Chemistry Letters, 29(7), 882-889.
DOI Scopus15 WoS13 Europe PMC10

Year Citation
2019 Modi, N. D., Tan, E., Wiese, M. D., Rowland, A., Sorich, M. J., & Hopkins, A. M. (2019). The effects of beta-blocker use in HER2-positive advanced breast cancer and implications on survival outcomes. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 15 (pp. 129-130). WILEY.
2019 Modi, N. D., Koczwara, B., Rowland, A., McKinnon, R. A., Wiese, M. D., Sorich, M. J., & Hopkins, A. M. (2019). Effect of bodymass index on survival outcomes of patients with HER-2 positive advanced breast cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 15 (pp. 128). WILEY.
  • PPK Research Services via Panel arrangement, Therapeutic Goods Administration, 16/04/2025 - 15/04/2028

Courses I teach

  • PHAR 1008 Health Professional Essentials (2025)
  • PHAR 2022 Pharmacology C (2025)

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Mrs Behdokhtsadat Alinaghian

Connect With Me

External Profiles

Other Links